Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 897 of 6351
-
Mobile health units aim to slash hypertension in black communities
Prevention OngoingBrief Summary: Black adults have a higher incidence of hypertension (HTN) and a greater risk of HTN-related cardiovascular disease (CVD) compared with White adults. Even mild elevations in blood (BP) above 115/75 mm Hg are associated with increased CVD risk. Accordingly, emphasi…
Sponsor: Wayne State University • Aim: Prevention
Last updated Jun 27, 2026 07:54 UTC
-
Experimental gene therapy targets duchenne MD in young boys
Disease control Stopped earlyThe study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can getting kids moving sooner in the ICU shorten their time on a ventilator?
Disease control Recruiting nowWhile mortality in U.S. pediatric intensive care units (PICUs) is improving, surviving children frequently develop persistent physical, cognitive, and psychological impairments. Over half of critically ill children experience potentially preventable PICU-acquired morbidities, wit…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New shot may simplify lung cancer treatment, phase 3 trial underway
Disease control OngoingThe purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This f…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug XmAb20717 tested in rare cancers – trial suspended
Disease control PausedTo test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Cooling time trial for kids after heart stopping: could longer be better?
Disease control Recruiting nowThis is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. The study team hypothesizes that longer durations of cooling may improve either the proportion …
Sponsor: University of Michigan • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
Can a common Anti-Inflammatory pill protect the heart and brain after a brain bleed?
Disease control CompletedThe overall goal is to establish the safety and efficacy of colchicine in ICH patients for the prevention of major cardiovascular events and brain injury. Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH) is a vanguard pilot tri…
Phase 2 • Sponsor: Population Health Research Institute • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could less chemo be enough for some kids with rhabdomyosarcoma?
Disease control Recruiting nowRhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to tame Sjogren's syndrome in major trial
Disease control OngoingA randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could less radiation be just as good for HPV throat cancer?
Disease control Recruiting nowThe purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, car…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New trial aims to give every blood cancer patient a donor
Disease control Recruiting nowThis study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use highly…
Phase 1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Eye drops aim to speed corneal healing after cataract surgery
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
Phase 3 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New bispecific antibody shows promise for unresectable liver cancer
Disease control CompletedPhase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
Phase 2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New COVID pill shows promise in large trial
Disease control CompletedThe main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for liver patients: drug may delay brain fog and hospital stays
Disease control OngoingStudy RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the prese…
Phase 3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
New hope for lung cancer patients whose current drug stops working
Disease control OngoingClinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treat…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for tough lymphomas: experimental drug STP938 enters human trials
Disease control Recruiting nowThe Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Phase 1/2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to slow advanced breast cancer
Disease control OngoingThis Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth f…
Phase 3 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets Hard-to-Treat cancer mutation
Disease control Recruiting nowThis is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRA…
Phase 1/2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Green light and pink dye take on tough eye infections
Disease control CompletedRose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone…
Phase 3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC